Emergent BioSolutionsvsMerck & Company

EBS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

EBS

Emergent BioSolutions Inc.

$5.75

Value $297M

-0.78%
EBS's page

MRK

Merck & Company, Inc.

$146.40

Value $362B

-1.02%
MRK's page

Emergent BioSolutions (EBS) has a market value of $297M and Merck & Company (MRK) $362B. Over the last year, with dividends, EBS moved -43.2% and MRK +62.2%. Dividend yield: EBS none, MRK 2.32%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EBS$297M

    MRK$362B

    MRK is 1,217 times EBS

  • Revenue, 12 months

    EBS$649M

    MRK$67.4B

    MRK is 104 times EBS

  • Net income, 12 months

    EBS-$261M

    MRK$2.5B

  • Operating margin

    EBS-27.7%

    MRK–

  • ROIC

    EBS-13.7%

    MRK3.9%

    17.6 points apart

  • P/E

    EBS–

    MRK147.6

  • Dividend yield

    EBS0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    EBS-84.9%

    MRK+103.8%

    188.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EBS-84.9%

MRK+103.8%

010020020222023202420252026
Returns by period
PeriodEBSWith dividendsMRKWith dividends
1 year since November 14, 2025-43.2%Price -43.2%+62.2%Price +57.6%
3 years since November 16, 2023+170.8%+39.4% a yearPrice +170.8%+57.3%+16.3% a yearPrice +43.5%
5 years since November 15, 2021-84.9%-31.4% a yearPrice -84.9%+103.8%+15.3% a yearPrice +74.9%
10 years since November 16, 2016-80.5%-15.1% a yearPrice -80.5%+232.4%+12.8% a yearPrice +145.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EBSEmergent BioSolutionsMRKMerck & Company

Valuation

EBSMRK
Valuation
Price$5.75$146.40
Market value$297M$362B
Enterprise value (EV)$629M$406B
P/E–147.6
P/E, 5-year median–14.8
P/B1.08.1
EV/EBIT–85.3
Free cash flow yield63.3%4.1%

Results and growth

EBSMRK
Results and growth
Revenue, 12 months$649M$67.4B
Net income, 12 months-$261M$2.5B
Free cash flow, 12 months$188M$14.7B
Earnings per share, 12 months-$5.02$0.98
Revenue growth, year on year-28.8%1.3%
Revenue growth a year, past-13.7%over 5 years+9.4%over 5 years
EPS growth a year, past-30.4%over 5 years+21.2%over 5 years

Margins and returns on capital

EBSMRK
Margins and returns on capital
Gross margin48.4%71.8%
Operating margin-27.7%–
Net margin-40.2%3.6%
ROIC-13.7%3.9%
ROE-57.1%5.2%

Balance sheet

EBSMRK
Balance sheet
Cash$176M$9.7B
Total debt$514M$53.8B
Net debt / EBITDA–5.7
Interest cover-4.0×2.4×

Dividends and buybacks

EBSMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield8.4%1.4%
Shareholder yield8.4%3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EBS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Emergent BioSolutions or Merck & Company?

By market value, Merck & Company ($362B) is about 1,217.0 times Emergent BioSolutions ($297M), at today's prices.

How did EBS and MRK stock do over the last 10 years?

Since November 16, 2016, EBS's price moved -80.5% and MRK's +145.0%. With dividends: EBS -80.5% (-15.1% a year), MRK +232.4% (+12.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, EBS or MRK?

The dividend yield at today's price is none for Emergent BioSolutions and 2.32% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Emergent BioSolutions or Merck & Company?

Over the last twelve months, the net margin was -40.2% for Emergent BioSolutions and 3.6% for Merck & Company, and the operating margin -27.7% and –. Revenue was $649M and $67.4B.

Which is the better investment, Emergent BioSolutions or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.